U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499323) titled 'Talquetamab in Patients With Refractory Generalized Myasthenia Gravis' on March 24.
Brief Summary: Myasthenia Gravis (MG) is a chronic autoimmune disease mediated by pathogenic antibodies. Approximately 10%-15% of patients present with refractory status, defined as having an inadequate response to existing therapies or an inability to tolerate the side effects of the medication, highlighting an urgent need for the development of more targeted innovative therapies. Talquetamab is a bispecific antibody that targets G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and the Cluster of Differentiation 3 (CD3) molecule on the ...